Filing Flows

Filing Flows › Companies › Assembly Biosciences › Cash flow

Assembly Biosciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$15.5M in Q2 2026 · −$38.6M over twelve months

Operating cash flow−$15.5M
Free cash flow−$15.5M

Analysis

In Q2 2026, Assembly Biosciences generated −$15.5M of operating cash flow. That is $1.3M more than in Q2 2025 (−$16.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$38.5M; the largest uses were other investing ($234M), operating cash flow ($38.5M), capital spending ($85K); besides operations, cash came from other financing ($281M), shares issued ($504K); the cash balance rose by $8.3M.

Operating cash flow was −$15.5M against net income of −$3.9M. The largest differences: deferred revenue −$12.8M, stock-based pay +$2.4M, prepaid and other assets −$1.2M.

Free cash flow

Assembly Biosciences: free cash flow by quarterAssembly Biosciences: free cash flow by quarter−$15.2MQ3 2024−$407KQ4 2024−$23.4MQ1 2025−$16.8MQ2 2025−$15.2MQ3 2025$14.2MQ4 2025−$22.1MQ1 2026−$15.5MQ2 2026
Operating cash flow less capital spending.
Assembly Biosciences: operating cash flow against capital spendingAssembly Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending−$15.2M$0Q3 2024−$407K$0Q4 2024−$23.4M$0Q1 2025−$16.8M$0Q2 2025−$15.1M$42KQ3 2025$14.2M$24KQ4 2025−$22.1M$19KQ1 2026−$15.5M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$15.5M, Capital spending $0.

Capital allocation, year by year

Assembly Biosciences: where the cash came from (up) and went (down), by fiscal yearAssembly Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$93.4MFY2021: Shares issued $52.8MFY2021: Asset sales $2.4MFY2021: Capital spending −$3.1M$55.2MFY2021FY2022: Operating cash flow −$84.5MFY2022: Shares issued $325KFY2022: Asset sales $1.5MFY2022: Capital spending −$102K$1.8MFY2022FY2023: Operating cash flow $22.7MFY2023: Shares issued $4.5MFY2023: Asset sales $24KFY2023: Capital spending −$255K$27.3MFY2023FY2024: Operating cash flow −$51.1MFY2024: Shares issued $2.0MFY2024: Capital spending −$28K$2.0MFY2024FY2025: Operating cash flow −$41.1MFY2025: Shares issued $2.0MFY2025: Capital spending −$66K$2.0MFY2025
Over these 5 years operating cash flow totalled −$247M; the largest uses were operating cash flow ($270M) and capital spending ($3.5M). Cash-flow statements as filed.

Where the cash came from and went

Assembly Biosciences: sources (+) and uses (−) of cash, Q2 2026Assembly Biosciences: sources (+) and uses (−) of cash, Q2 2026Other financing$109MOther investing−$92.1MOperating cash flow−$15.5MCash drawn (+) / kept (−)−$1.2MShares issued$230K
Assembly Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Assembly Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$281MOther investing−$234MOperating cash flow−$38.5MCash drawn (+) / kept (−)−$8.3MShares issued$504KCapital spending−$85K

From profit to cash

Assembly Biosciences: net income to operating cash flow, Q2 2026Assembly Biosciences: net income to operating cash flow, Q2 2026Net income−$3.9MDepreciation & amortization$20KStock-based pay$2.4MReceivables−$371KPayables−$70KAccrued liabilities$678KDeferred revenue−$12.8MPrepaid and other assets−$1.2MOperating cash flow−$15.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$15.5M—$230K−$1.2M−$15.5M
Q1 2026−$22.1M−$19K$149K$27.3M−$22.1M
Q4 2025$14.2M−$24K$88K−$35.9M$14.2M
Q3 2025−$15.1M−$42K$37K$1.5M−$15.2M
Q2 2025−$16.8M——−$593K−$16.8M
Q1 2025−$23.4M—$1.9M$14.9M−$23.4M
Q4 2024−$407K—$2.0M−$9.9M−$407K
Q3 2024−$15.2M——−$9.2M−$15.2M

Assembly Biosciences: income statement and cash flow

Assembly Biosciences, Q2 2026: revenue $13.4M (+39% year over year), operating margin -47.4%. The chart follows the revenue to costs, profit and cash.

Assembly Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.